BHCM
RLMD icon

Brevan Howard Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Brevan Howard Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-73,595
Closed -$512K – 2505
2026
Q1 		$512K Buy
+73,595
New +$348K ﹤0.01% 1293
2024
Q2 		– Sell
-14,918
Closed -$69.4K – 1356
2024
Q1 		$69.4K Buy
+14,918
New +$71.9K ﹤0.01% 922

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brevan Howard Capital Management's RLMD Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 73,595 shares — an estimated $512K sold.

Brevan Howard Capital Management first reported a position in RLMD in Q1 2024 and held it in 2 quarters. The position peaked at $512K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 73,595 Relmada Therapeutics shares in Q2 2026, an estimated $512K.
  • Brevan Howard Capital Management first reported a position in Relmada Therapeutics in Q1 2024 and held it in 2 quarters.
  • Brevan Howard Capital Management's Relmada Therapeutics position peaked at $512K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.